Schonfeld Strategic Advisors LLC Humanigen, Inc Transaction History

Schonfeld Strategic Advisors LLC

  • $13.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$1.76 - $3.33 $21,648 - $40,959
-12,300 Reduced 12.63%
85,100 $151,000
Q1 2022

May 16, 2022
BUY
$1.81 - $3.97 $176,294 - $386,678
97,400 New
97,400 $293,000
Q3 2021

Nov 16, 2021
SELL
$5.93 - $17.83 $70,567 - $212,176
-11,900 Closed
0 $0
Q2 2021

Nov 16, 2021
SELL
$13.54 - $22.74 $20,310 - $34,110
-1,500 Reduced 11.19%
11,900 $207,000
Q2 2021

Aug 16, 2021
BUY
$13.54 - $22.74 $181,436 - $304,716
13,400 New
13,400 $233,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email